His scientific interests lie mostly in Survivin, Cancer research, Cell biology, Apoptosis and Programmed cell death. His Survivin research is multidisciplinary, incorporating perspectives in Inhibitor of apoptosis, Cell cycle, Mitosis and Cell growth. His studies in Cancer research integrate themes in fields like CD34, MEK inhibitor and Apoptosis Inhibitor.
His Cell biology study combines topics in areas such as Tumor progression, Hsp90 and XIAP. Dario C. Altieri interconnects Immunohistochemistry, Molecular biology, HeLa and In vivo in the investigation of issues within Apoptosis. His Programmed cell death research incorporates elements of Autophagy, Cell division, Colorectal cancer, Mitochondrion and Physiology.
Dario C. Altieri spends much of his time researching Survivin, Cancer research, Cell biology, Apoptosis and Molecular biology. His work deals with themes such as Cell growth, Inhibitor of apoptosis, Programmed cell death, Mitosis and Cell cycle, which intersect with Survivin. His Cancer research research includes elements of Carcinogenesis, Cancer, Prostate cancer and Immunology.
His research in Cell biology focuses on subjects like Cell adhesion, which are connected to Cell adhesion molecule. His Apoptosis study frequently draws connections to adjacent fields such as In vivo. His work in Molecular biology tackles topics such as Thrombin which are related to areas like Tissue factor.
Dario C. Altieri mainly investigates Mitochondrion, Cancer research, Cell biology, Cancer and Metastasis. His Mitochondrion research includes themes of Apoptosis, Protein kinase B, PI3K/AKT/mTOR pathway, Cell growth and Reprogramming. His study in Cancer research is interdisciplinary in nature, drawing from both Tumor microenvironment, Immunology, Combination therapy, Prostate cancer and Programmed cell death.
His Cell biology research is multidisciplinary, incorporating elements of Cancer cell, Cell and Survivin. Dario C. Altieri has included themes like Inhibitor of apoptosis, Small hairpin RNA, Angiogenesis and Cell division in his Survivin study. His Cancer research is multidisciplinary, incorporating perspectives in Disease and Pharmacology.
Dario C. Altieri focuses on Mitochondrion, Cancer research, Cell biology, Apoptosis and Autophagy. As a part of the same scientific family, Dario C. Altieri mostly works in the field of Mitochondrion, focusing on Phosphorylation and, on occasion, Signal transduction, Bioenergetics and Proteostasis. Dario C. Altieri combines subjects such as Cancer, Tumor progression, Hsp90 and Disease with his study of Cancer research.
While the research belongs to areas of Disease, Dario C. Altieri spends his time largely on the problem of Inhibitor of apoptosis, intersecting his research to questions surrounding Survivin. His Cell biology research focuses on Metastasis and how it connects with Kinesin, Adaptation and Druggability. His work investigates the relationship between Autophagy and topics such as Computational biology that intersect with problems in Programmed cell death and Multicellular organism.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)
Daniel J. Klionsky;Amal Kamal Abdel-Aziz;Sara Abdelfatah;Mahmoud Abdellatif.
Autophagy (2021)
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
Daniel J. Klionsky;Kotb Abdelmohsen;Akihisa Abe;Joynal Abedin.
Autophagy (2016)
A novel anti-apoptosis gene, survivin , expressed in cancer and lymphoma
Grazia Ambrosini;Colette Adida;Dario C. Altieri.
Nature Medicine (1997)
Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356
Daniel J. Klionsky;Kotb Abdelmohsen;Akihisa Abe;Joynal Abedin.
Autophagy (2016)
Control of apoptosis and mitotic spindle checkpoint by survivin.
Fengzhi Li;Grazia Ambrosini;Emily Y. Chu;Janet Plescia.
Nature (1998)
Validating survivin as a cancer therapeutic target.
Dario C. Altieri.
Nature Reviews Cancer (2003)
Inhibition of Apoptosis by Survivin Predicts Shorter Survival Rates in Colorectal Cancer
Hiroshi Kawasaki;Dario C. Altieri;Cai-De Lu;Masao Toyoda.
Cancer Research (1998)
Survivin, versatile modulation of cell division and apoptosis in cancer
Dario C Altieri.
Oncogene (2003)
Survivin, cancer networks and pathway-directed drug discovery
Dario C. Altieri.
Nature Reviews Cancer (2008)
Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation.
C. Adida;P. L. Crotty;J. McGrath;D. Berrebi.
American Journal of Pathology (1998)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Thomas Jefferson University
Scripps Research Institute
AstraZeneca (United Kingdom)
The Wistar Institute
University of California, San Francisco
University of Vermont
University of Vermont
Cleveland Clinic Lerner College of Medicine
Yale University
Vita-Salute San Raffaele University
Australian National University
Hebrew University of Jerusalem
University of Tokyo
Pohang University of Science and Technology
University of Massachusetts Lowell
University of Kansas
Michigan State University
Iowa State University
Imperial College London
University of Göttingen
Mammal Research Institute
University of Genoa
Massey University
Institució Catalana de Recerca i Estudis Avançats
Kyoto University
San Francisco State University